Ascendis Pharma A (ASND) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Ascendis Pharma A (ASND) over the last 12 years, with Q4 2025 value amounting to -$39.6 million.
- Ascendis Pharma A's Net Income towards Common Stockholders rose 356.67% to -$39.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$166.8 million, marking a year-over-year decrease of 15086.67%. This contributed to the annual value of -$261.7 million for FY2025, which is 3522.58% up from last year.
- As of Q4 2025, Ascendis Pharma A's Net Income towards Common Stockholders stood at -$39.6 million, which was up 356.67% from -$73.1 million recorded in Q3 2025.
- Ascendis Pharma A's 5-year Net Income towards Common Stockholders high stood at $176.6 million for Q3 2023, and its period low was -$211.6 million during Q4 2022.
- In the last 5 years, Ascendis Pharma A's Net Income towards Common Stockholders had a median value of -$74.4 million in 2025 and averaged -$28.9 million.
- Per our database at Business Quant, Ascendis Pharma A's Net Income towards Common Stockholders tumbled by 25224.72% in 2023 and then skyrocketed by 21873.17% in 2024.
- Over the past 5 years, Ascendis Pharma A's Net Income towards Common Stockholders (Quarter) stood at -$121.3 million in 2021, then crashed by 74.41% to -$211.6 million in 2022, then skyrocketed by 55.07% to -$95.1 million in 2023, then skyrocketed by 56.77% to -$41.1 million in 2024, then rose by 3.57% to -$39.6 million in 2025.
- Its Net Income towards Common Stockholders was -$39.6 million in Q4 2025, compared to -$73.1 million in Q3 2025 and $45.6 million in Q2 2025.